Clinical utility of transarterial infusion chemotherapy using cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma. 2012

Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
Department of Gastroenterology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan.

BACKGROUND We evaluated the clinical efficacy of transarterial infusion chemotherapy using a cisplatin-lipiodol emulsion for unresectable hepatocellular carcinoma (HCC). METHODS Fifty-seven patients with advanced HCC, with no indications for surgical resection or local ablative therapy, such as percutaneous ethanol injection and radiofrequency ablation, were enrolled in this retrospective study. RESULTS Twelve patients were treated with cisplatin-alone at a dose of 65 mg/m(2) by infusion into the artery. Forty-two patients were treated with the same dose of cisplatin suspended in 1-10 ml of lipiodol (C/LPD). Cumulative survival rates in the cisplatin-treated group were 46.2% at one year, and 18.5% at two years, whereas these in the C/LPD group were 81.6% and 44.4%, respectively, with a significant difference between the two groups (p<0.01). In the cisplatin-treated group (n=13), no (0%) patients had a complete response (CR), two (15%) a partial response (PR), three (23%) no change (NC), and eight (62%) progressive disease (PD). In the C/LPD group (n=44), four (9%) patients had CR, 16 (35%) PR, 12 (26%) NC, and 12 (26%) PD. CR and PR were seen in 15% of the cisplatin-treated group and in 44% of the C/LPD group. C/LPD was significantly more effective than cisplatin-alone (p=0.039). Some patients showed tumor response to C/LPD after intra-arterial infusion of low-dose 5-fluorouracil. CONCLUSIONS C/LPD produced superior effects compared to cisplatin-alone for unresectable HCC, causing no major side-effects, and increasing the survival rate.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D004998 Ethiodized Oil Ethyl ester of iodinated fatty acid of poppyseed oil. It contains 37% organically bound iodine and has been used as a diagnostic aid (radiopaque medium) and as an antineoplastic agent when part of the iodine is 131-I. (From Merck Index, 11th ed) Ethiodized Oil (Injection),Ethiodized Oils,Ethiodized Poppy Seed Oil,Ethiodol,Lipiodol,Lipiodol UltraFluid,Oil, Ethiodized,Oils, Ethiodized,UltraFluid, Lipiodol
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas

Related Publications

Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
July 2009, Cardiovascular and interventional radiology,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
March 2010, AJR. American journal of roentgenology,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
February 2011, AJR. American journal of roentgenology,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
September 2007, Gan to kagaku ryoho. Cancer & chemotherapy,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
May 2002, Hepatology (Baltimore, Md.),
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
August 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
February 1998, Gan to kagaku ryoho. Cancer & chemotherapy,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
February 2014, Gan to kagaku ryoho. Cancer & chemotherapy,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
May 2008, ANZ journal of surgery,
Tetsuya Beppu, and Kazushi Sugimoto, and Katsuya Shiraki, and Masahiko Tameda, and Yuji Inagaki, and Suguru Ogura, and Chika Kasai, and Satoko Kusagawa, and Keiichiro Nojiri, and Misao Yoneda, and Hiroyuki Fuke, and Norihiko Yamamoto, and Yoshiyuki Takei, and Masashi Fujimori, and Takaaki Hasegawa, and Takashi Yamanaka, and Junichi Uraki, and Masataka Kashima, and Haruyuki Takaki, and Atsuhiro Nakatsuka, and Koichiro Yamakado, and Kan Takeda
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!